MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.700
+0.025
+1.49%
After Hours: 1.720 +0.02 +1.17% 18:49 03/21 EDT
OPEN
1.730
PREV CLOSE
1.675
HIGH
1.746
LOW
1.560
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
6.63
52 WEEK LOW
1.560
MARKET CAP
452.42M
P/E (TTM)
-1.9658
1D
5D
1M
3M
1Y
5Y
1D
Autolus Therapeutics: Positive Momentum Amid Financial Challenges
TipRanks · 2d ago
Autolus Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 2d ago
Autolus Therapeutics Price Target Cut to $6.00/Share From $8.00 by Wells Fargo
Dow Jones · 2d ago
Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $6
Benzinga · 2d ago
Autolus Therapeutics price target lowered to $6 from $8 at Wells Fargo
TipRanks · 2d ago
Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)
TipRanks · 2d ago
Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects
TipRanks · 2d ago
Autolus Therapeutics Reports Strong 2024 Results
TipRanks · 3d ago
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.